Navigation Links
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals

SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Ortho-McNeil) initiated under their partnership a first-in-human Phase 1 clinical trial of APD597, a novel oral drug candidate discovered by Arena that targets the glucose-dependent insulinotropic receptor (GDIR) for the treatment of type 2 diabetes. The GDIR was also discovered by Arena and has the potential to stimulate insulin release in response to increases in blood glucose.

"The GDIR is a promising and exciting target for the treatment of type 2 diabetes. We look forward to continuing to work with Ortho-McNeil on APD597 as it advances in the clinic," stated Jack Lief, Arena's President and Chief Executive Officer.

Ortho-McNeil's Phase 1 program will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of APD597 in single and multiple ascending dose studies in healthy volunteers. Ortho-McNeil's planned clinical studies will also include the evaluation of patients with type 2 diabetes.

Aboutthe Glucose-Dependent Insulinotropic Receptor (GDIR)

The GDIR is an orphan G protein-coupled receptor (GPCR), discovered by Arena. It is expressed in beta cells, the cells in the pancreas responsible for producing insulin in response to increases in blood glucose. The GDIR signals through a similar intracellular pathway as the GLP-1 receptor, with common downstream effects, but unlike the GLP-1 receptor, the GDIR has proven amenable to small molecule drug discovery. Stimulation of the GDIR is intended to more efficiently promote insulin release by beta cells in response to elevated blood glucose levels. In addition, the GDIR is expressed in cells other than pancreatic beta cells, such as endocrine cells in the gastrointestinal tract, and in preclinical studies the GDIR stimulates the release of GLP and GIP, two incretins that play an important role in insulin regulation and glucose homeostasis. GDIR stimulation has also been found to increase the levels and activity of intracellular factors thought to be involved in the preservation of beta cells, and GDIR signaling may therefore also serve to maintain beta cell mass in type 2 diabetes.

About Diabetes

Diabetes is a major worldwide disease. The International Diabetes Federation estimates that in 2007 there were 246 million adults with diabetes worldwide, an increase of over 20% since 2003. Approximately 90%, or 221 million, of diabetics worldwide suffer from type 2 diabetes, the adult-onset form of the disease. Type 2 diabetes is characterized by inadequate response to insulin or inadequate secretion of insulin as blood glucose levels rise. Therapies for type 2 diabetes are directed toward correcting the body's inadequate response with oral or injectable medications, or directly modifying insulin levels by injection of insulin or insulin analogs.

The worldwide market for diabetes medications exceeded $12 billion in 2005, of which oral drugs exceeded $7 billion. Current oral medications for type 2 diabetes have limitations including side effects and safety issues prompting continued efforts to develop therapeutics to improve the treatment of diabetes.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about APD597's development, therapeutic indication, efficacy and potential; the potential of the GDIR, including the potential to stimulate insulin release in response to increases in blood glucose; future activities under Arena's collaboration with Ortho-McNeil; the protocol, design, scope, enrollment and other aspects of the Phase 1 program for APD597; the inclusion of the evaluation of patients with type 2 diabetes in the planned clinical studies; and about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to receive regulatory approval for its drug candidates, Arena's ability to partner lorcaserin or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Contacts:  Jack Lief                              Mary Claire Duch
               President and CEO                      WeissComm Partners
                                                      Media Relations
               David Walsey                           212.301.7228
               Director, Corporate Communications

               Arena Pharmaceuticals, Inc.
               858.453.7200, ext. 1682

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
(Date:10/9/2015)... 9, 2015 --> ... announced its execution of an Intellectual Property & Subsidiary Assignment and ... Inc. a Delaware Corporation, related party, and a majority ... --> --> These agreements were executed ... whereby the Research and Development components shall now be ...
(Date:10/9/2015)... -- Henry Schein , Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... Disaster Relief Hotline is open for dentists, physicians and ... a result of the disastrous flooding in ... Henry Schein customers is 800-999-9729. The Hotline ...
(Date:10/9/2015)... 2015  Hi-Tech Pharmaceuticals ("Hi-Tech"), a leading global ... iForce Nutrition ("iForce"), one of the fastest-growing Sports Nutrition ... , today announced that they have entered into ... to acquire iForce. The transaction will enhance Hi-Tech,s ... through iForce,s strong distribution network. Jared ...
Breaking Medicine Technology:
... BROOKFIELD, Wis., March 1, 2012 The Food and ... to treat female urinary incontinence. "InTone ... the millions of women who have incontinence issues," said ... LLC, and inventor of InTone.  "With InTone, we believe ...
... the Pharmacy Technician Certification Board (PTCB) ... from the pharmacy profession on recommended changes to ... of specialty pharmacy technician exams and additional requirements ... period of practical experience, criminal background checks, and ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... Matrix IT ... product specifications for TRACTUS, the world’s first sterile field scanner. , ... response to the FDA’s recent Unique Device Identifier (UDI) Final Rule, which will ...
(Date:10/9/2015)... , ... October 09, 2015 , ... The Asthma and ... US Centers for Disease Control and Prevention (CDC) to improve the knowledge and skills ... AAFA has been awarded a project by the CDC and allows AAFA to continue ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... New Orleans and the surrounding communities, is initiating a combined charity effort with ... for unwanted animals in southern Louisiana. , Animal Rescue New Orleans is ...
(Date:10/9/2015)... ... October 09, 2015 , ... Prescription Hope, the fastest ... of life to save money on the high cost of their prescription medications ... medication, individuals and families can receive their medications delivered direct from over 180 ...
(Date:10/9/2015)... ... 09, 2015 , ... ViewPoint Center, a teen mental health hospital ... illness, the stigma associated with mental illness causes many to hide away in shame ... of supporting teens with mental illness , providing teens with comprehensive diagnostic assessment ...
Breaking Medicine News(10 mins):
... seen for women with history of early delivery, researchers say ... supplements are believed to have many health benefits, but the ... history of delivering their babies early carry their next child ... not add any benefit," said study author Dr. Margaret Harper, ...
... seemingly smug married couples who constantly refer to themselves ... of California, Berkeley, suggests that spouses who use "we-ness" ... who don,t. UC Berkeley researchers analyzed conversations between ... in their marriages and found that those who used ...
... Anonymous (AA) meetings helps people with alcohol use disorders stay sober ... has found that study participants who attended AA meetings more frequently ... than did those with less AA participation. The report will ... online. "Our study is one of the first ...
... new study by researchers at UCLA and Brigham and Women,s ... the past decade have resulted in fewer cases of ear ... of the most common illnesses among children, with annual direct ... the United States. "We believe these ...
... ... pushes total men,s health to the forefront , ... (PRWEB) January 28, 2010 -- Dr. Florence Comite ... University School of Medicine, most recently as an Associate Clinical Professor. With these impeccable ...
... U.S. HealthWorks, a ... appointed Jeanne Osterlund head of sales for the 128 U.S. HealthWorks Medical Group centers nationwide ... Valencia, CA (Vocus) January ... care centers in the nation, announced today that it has appointed Jeanne Osterlund head ...
Cached Medicine News:
CPTMeister is a coding reference based on the Physicians' Current Procedural Terminology (CPT) codes developed by the American Medical Association. It is an iSilo document composed of more than 2,000...
The BluefishRx ICD-9 is a Palm OS code lookup tool which incorporates the ICD-9 code set with the full and short code descriptions. It includes a multi keyword search tool with a dictionary of over 2...
MD Coder v 6.0 is a charge capture for the Palm OS and Pocket PC operating systems. We have integrated the feedback from hospitals and physicians. MD Coder v 6.0 comes in three versions: Physician Ba...
Preferred Health Resourses Practice Management System is called Remedy. The PDA version is Remedy for the Palm. It is a data capture program for your medical billing....
Medicine Products: